Authored By: Sarah
11 Jul 2024

 Pulmonary Embolism Therapeutics Market Size to grow by USD 14020.7 million between 2024-2028

According to a research report “ Pulmonary Embolism Therapeutics Market” by Application (Hospitals, Ambulatory surgical centers, Research institutes) Route Of Administration (Oral, Parenteral) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 14020.7 million, at a CAGR of  10.93% during the forecast period. The global pulmonary embolism therapeutics market is experiencing significant growth due to the rising prevalence of pulmonary embolism diseases. This condition, characterized by a blood clot obstructing a lung artery, can be life-threatening and is particularly prevalent among individuals with a history of blood clots or inherited medical disorders, as well as those suffering from chronic diseases such as cardiovascular conditions and respiratory problems. The increasing incidence of risk factors for pulmonary embolism, including heart disease, cancer, and obesity, further fuels market expansion.

Browse market data tables, figures, and in-depth TOC on “Pulmonary Embolism Therapeutics Market” by Application (Hospitals, Ambulatory surgical centers, Research institutes) Route Of Administration (Oral, Parenteral) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Application, the Hospitals segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Route Of Administration, Oral  segment is expected to hold the largest market size for the year 2024

The global pulmonary embolism therapeutics market is poised for significant growth, driven in part by the expansion of specialized hospitals and clinics offering these treatments. With advanced medical infrastructure and a high demand for high-quality medical products and consumables, large healthcare facilities are key contributors to market growth. The rising prevalence of pulmonary embolism and associated risk factors, coupled with an aging population, further bolsters market expansion. Technological innovations, such as Huawei's smart wearable devices for monitoring blood oxygen and generating electrocardiograms, enhance the reliability and accessibility of pulmonary embolism therapeutics, making them increasingly essential in hospitals and clinics.

North America is forecasted to hold the largest market size by region in 2024

The Pulmonary Embolism (PE) therapeutics market represents a significant business opportunity for pharmaceutical companies, given the high prevalence of PE and the need for effective treatments. PE, a serious condition caused by a blockage in the pulmonary artery, can lead to severe respiratory complications and even death if left untreated. Current treatments include anticoagulants, thrombolytics, and mechanical thrombectomy devices. Market growth is driven by an aging population, increasing incidence of PE, and the launch of novel therapeutics. Companies such as Bayer AG, Boehringer Ingelheim, and Daiichi Sankyo are key players in this market.

The Pulmonary Embolism Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Anthos Therapeutics
  • argenx SE
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Inari Medical Inc.
  • Johnson and Johnson Services Inc.
  • Medtronic Plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Pulmonary Embolism (PE) Therapeutics Market is witnessing significant growth due to the increasing incidence of PE, a life-threatening condition caused by blood clots obstructing the pulmonary artery or its branches. Key drivers of the market include research institutes focusing on developing novel therapeutics and advances in diagnostic technologies. PE can result from deep vein thrombosis (DVT) in the leg or pelvic veins, which can occur due to various risk factors such as family history, hormone replacement treatment, high blood pressure, obesity, overweight, smoking, old age pregnancy, and immobility. Symptoms of PE include chest discomfort, shortness of breath, cough, cyanosis, fever, dizziness, irregular heartbeat, and chest pain. PE diagnosis involves MRI, ECG, and Chest X Ray. PE treatment includes anticoagulants administered via parenteral or oral routes to prevent clot growth and dissolve existing clots. Reimbursement policies and healthcare infrastructure development in ambulatory surgical centers are also driving market growth. Key challenges include the risk of bleeding complications and the need for long-term anticoagulation therapy.

Market Research Overview

Pulmonary Embolism (PE) is a life-threatening condition caused by blood clots that block the pulmonary artery or its branches in the lungs. PE is often a complication of Deep Vein Thrombosis (DVT), which can form in the deep veins of the legs or pelvis. The global Pulmonary Embolism Therapeutics Market is witnessing significant growth due to the increasing prevalence of risk factors such as aging population, job pressure, lung diseases, family history, hormone replacement treatment, high blood pressure, obesity, smoking, old age pregnancy, and overweight. Key therapeutic approaches include medications administered via the parenteral and oral routes, mechanical devices, and surgery. Notable medications include Fortelizin, which is under clinical trial studies at various research institutes and organizations. Reimbursement policies vary across ambulatory surgical centers, hospitals, online pharmacies, retail pharmacies, homecare, specialty clinics, and healthcare professionals. PE symptoms include persistent cough, chest discomfort, shortness of breath, cyanosis, fever, dizziness, irregular heartbeat, cough, and chest pain. Diagnostic tools include D-dimer test, venous ultrasound, venography, pulmonary angiography, CT scan, MRI, ECG, and chest X-ray. PE can lead to lung and heart damage, cancer, and even death. The World Health Organization emphasizes the importance of early diagnosis and treatment to prevent complications and reduce healthcare expenditure. Chemotherapy and cancer are also associated with PE due to the increased risk of blood clots. Drug approvals and patient epidemiology are crucial factors driving market growth.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio